Uterine Papillary Serous Carcinoma (UPSC): A Clinicopathologic Study of 30 Cases

• Published in: Gynecologic oncology 1995-12, Vol.59 (3), p.384-389
• Main Authors: Kato, Daniel T., Ferry, Judith A., Goodman, Annekathryn, Sullinger, Jana, Scully, Robert E., Goff, Barbara A., Fuller, Jr, Arlan F., Rice, Laurel W.
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Biological and medical sciences; Combined Modality Therapy; Cystadenocarcinoma, Papillary - pathology; Cystadenocarcinoma, Papillary - radiotherapy; Cystadenocarcinoma, Papillary - surgery; Female; Female genital diseases; Gynecology. Andrology. Obstetrics; Humans; Medical sciences; Middle Aged; Survival Analysis; Tumors; Uterine Neoplasms - pathology; Uterine Neoplasms - radiotherapy; Uterine Neoplasms - surgery
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1006/gyno.1995.9957

Between 1975 and 1989, 896 patients were treated for endometrial carcinoma at the Massachusetts General Hospital. Thirty patients were identified from the tumor registry as having uterine papillary serous carcinomas. The survival for all patients and for groups of patients stratified on clinical and pathological parameters was examined in the Kaplan–Meier survival curves. Curves for the different strata were compared using the logrank test. The 5-year survival for the 30 patients was 30% ± 9%. Patients with surgical stage I and II tumors had a 5-year survival rate of 79% ± 14% compared to 25% ± 10% in patients with stage III and IV tumors (P= 0.02). Clinical stage, depth of myometrial invasion, lymph–vascular space invasion, tumor grade, and DNA aneuploidy were not found to significantly impact on survival. However, a survival advantage was seen in patients diagnosed with early surgical stage tumors, reinforcing the need for thorough staging at the time of laparotomy.